Elizabeth Swisher, MD of University of Washington Medical Center discusses the treatment trends for ovarian cancer for 2017. She highlights the use of FDA-approved PARP inhibitors, immunotherapy, and even combination therapy with PARP inhibitors and immunotherapy. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Treatment Trends for 2017: PARP Inhibitors and Immunotherapy for Gynecologic Cancers
